Drug intelligence / Profile preview

hydrocodone + acetaminophen + promethazine

Development stage
Phase 3
Lead developer
Charleston Laboratories
Modality
Small Molecules
Administration
Oral
01

Overview

This immediate-release combination drug contains **hydrocodone** (a semi-synthetic opioid agonist for pain relief), **acetaminophen** (a non-opioid analgesic and antipyretic), and **promethazine** (a first-generation antihistamine with antiemetic, sedative, and anti-allergic properties). Hydrocodone acts as a mu-opioid receptor agonist to reduce pain perception, acetaminophen provides analgesia and fever reduction via central mechanisms, and promethazine, an H1 histamine receptor antagonist, reduces nausea (notably opioid-induced nausea/vomiting), provides additional mild sedation, and may reduce allergic responses. This combination (marketed as Hydexor) was developed specifically for the **short-term management of acute pain** that requires an opioid, particularly in patients prone to opioid-induced nausea and vomiting, with the goal of addressing both pain and opioid-related side effects[2].

Brand names
Hydexor
Other names
hydrocodone acetaminophen promethazine
02

Targets

DOR (Opioid Receptor Delta 1)ALB (Human serum albumin)HRH1 (Histamine H1 Receptor)MOR (Mu opioid receptor)COX

Beyond the preview

Go deeper on hydrocodone + acetaminophen + promethazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydrocodone + acetaminophen + promethazine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call